XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

X4 Pharmaceuticals Inc (XFOR) navigates a challenging landscape with strategic cost reductions and promising product ...

HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note published on Thursday morning,Benzinga reports. They currently have a $1. ...

Shares of NASDAQ XFOR opened at $0.27 on Wednesday. The company has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $0.53. The company has a debt-to-equity ratio of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and ...

Stay updated on market trends for XFOR. FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder FDA approves Xolremdi capsules for WHIM syndrome ...

$XFOR ($XFOR) is expected to release its quarterly earnings data on Tuesday, March 25th before market open, per Finnhub. Analysts are expecting revenue of $1,061,820 ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 20 ...